Cargando…
Laboratory evaluation of twelve portable devices for medicine quality screening
BACKGROUND: Post-market surveillance is a key regulatory function to prevent substandard and falsified (SF) medicines from being consumed by patients. Field deployable technologies offer the potential for rapid objective screening for SF medicines. METHODS AND FINDINGS: We evaluated twelve devices:...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483346/ https://www.ncbi.nlm.nih.gov/pubmed/34591844 http://dx.doi.org/10.1371/journal.pntd.0009360 |
_version_ | 1784577102967734272 |
---|---|
author | Zambrzycki, Stephen C. Caillet, Celine Vickers, Serena Bouza, Marcos Donndelinger, David V. Geben, Laura C. Bernier, Matthew C. Newton, Paul N. Fernández, Facundo M. |
author_facet | Zambrzycki, Stephen C. Caillet, Celine Vickers, Serena Bouza, Marcos Donndelinger, David V. Geben, Laura C. Bernier, Matthew C. Newton, Paul N. Fernández, Facundo M. |
author_sort | Zambrzycki, Stephen C. |
collection | PubMed |
description | BACKGROUND: Post-market surveillance is a key regulatory function to prevent substandard and falsified (SF) medicines from being consumed by patients. Field deployable technologies offer the potential for rapid objective screening for SF medicines. METHODS AND FINDINGS: We evaluated twelve devices: three near infrared spectrometers (MicroPHAZIR RX, NIR-S-G1, Neospectra 2.5), two Raman spectrometers (Progeny, TruScan RM), one mid-infrared spectrometer (4500a), one disposable colorimetric assay (Paper Analytical Devices, PAD), one disposable immunoassay (Rapid Diagnostic Test, RDT), one portable liquid chromatograph (C-Vue), one microfluidic system (PharmaChk), one mass spectrometer (QDa), and one thin layer chromatography kit (GPHF-Minilab). Each device was tested with a series of field collected medicines (FCM) along with simulated medicines (SIM) formulated in a laboratory. The FCM and SIM ranged from samples with good quality active pharmaceutical ingredient (API) concentrations, reduced concentrations of API (80% and 50% of the API), no API, and the wrong API. All the devices had high sensitivities (91.5 to 100.0%) detecting medicines with no API or the wrong API. However, the sensitivities of each device towards samples with 50% and 80% API varied greatly, from 0% to 100%. The infrared and Raman spectrometers had variable sensitivities for detecting samples with 50% and 80% API (from 5.6% to 50.0%). The devices with the ability to quantitate API (C-Vue, PharmaChk, QDa) had sensitivities ranging from 91.7% to 100% to detect all poor quality samples. The specificity was lower for the quantitative C-Vue, PharmaChk, & QDa (50.0% to 91.7%) than for all the other devices in this study (95.5% to 100%). CONCLUSIONS: The twelve devices evaluated could detect medicines with the wrong or none of the APIs, consistent with falsified medicines, with high accuracy. However, API quantitation to detect formulations similar to those commonly found in substandards proved more difficult, requiring further technological innovation. |
format | Online Article Text |
id | pubmed-8483346 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-84833462021-10-01 Laboratory evaluation of twelve portable devices for medicine quality screening Zambrzycki, Stephen C. Caillet, Celine Vickers, Serena Bouza, Marcos Donndelinger, David V. Geben, Laura C. Bernier, Matthew C. Newton, Paul N. Fernández, Facundo M. PLoS Negl Trop Dis Research Article BACKGROUND: Post-market surveillance is a key regulatory function to prevent substandard and falsified (SF) medicines from being consumed by patients. Field deployable technologies offer the potential for rapid objective screening for SF medicines. METHODS AND FINDINGS: We evaluated twelve devices: three near infrared spectrometers (MicroPHAZIR RX, NIR-S-G1, Neospectra 2.5), two Raman spectrometers (Progeny, TruScan RM), one mid-infrared spectrometer (4500a), one disposable colorimetric assay (Paper Analytical Devices, PAD), one disposable immunoassay (Rapid Diagnostic Test, RDT), one portable liquid chromatograph (C-Vue), one microfluidic system (PharmaChk), one mass spectrometer (QDa), and one thin layer chromatography kit (GPHF-Minilab). Each device was tested with a series of field collected medicines (FCM) along with simulated medicines (SIM) formulated in a laboratory. The FCM and SIM ranged from samples with good quality active pharmaceutical ingredient (API) concentrations, reduced concentrations of API (80% and 50% of the API), no API, and the wrong API. All the devices had high sensitivities (91.5 to 100.0%) detecting medicines with no API or the wrong API. However, the sensitivities of each device towards samples with 50% and 80% API varied greatly, from 0% to 100%. The infrared and Raman spectrometers had variable sensitivities for detecting samples with 50% and 80% API (from 5.6% to 50.0%). The devices with the ability to quantitate API (C-Vue, PharmaChk, QDa) had sensitivities ranging from 91.7% to 100% to detect all poor quality samples. The specificity was lower for the quantitative C-Vue, PharmaChk, & QDa (50.0% to 91.7%) than for all the other devices in this study (95.5% to 100%). CONCLUSIONS: The twelve devices evaluated could detect medicines with the wrong or none of the APIs, consistent with falsified medicines, with high accuracy. However, API quantitation to detect formulations similar to those commonly found in substandards proved more difficult, requiring further technological innovation. Public Library of Science 2021-09-30 /pmc/articles/PMC8483346/ /pubmed/34591844 http://dx.doi.org/10.1371/journal.pntd.0009360 Text en © 2021 Zambrzycki et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Zambrzycki, Stephen C. Caillet, Celine Vickers, Serena Bouza, Marcos Donndelinger, David V. Geben, Laura C. Bernier, Matthew C. Newton, Paul N. Fernández, Facundo M. Laboratory evaluation of twelve portable devices for medicine quality screening |
title | Laboratory evaluation of twelve portable devices for medicine quality screening |
title_full | Laboratory evaluation of twelve portable devices for medicine quality screening |
title_fullStr | Laboratory evaluation of twelve portable devices for medicine quality screening |
title_full_unstemmed | Laboratory evaluation of twelve portable devices for medicine quality screening |
title_short | Laboratory evaluation of twelve portable devices for medicine quality screening |
title_sort | laboratory evaluation of twelve portable devices for medicine quality screening |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483346/ https://www.ncbi.nlm.nih.gov/pubmed/34591844 http://dx.doi.org/10.1371/journal.pntd.0009360 |
work_keys_str_mv | AT zambrzyckistephenc laboratoryevaluationoftwelveportabledevicesformedicinequalityscreening AT cailletceline laboratoryevaluationoftwelveportabledevicesformedicinequalityscreening AT vickersserena laboratoryevaluationoftwelveportabledevicesformedicinequalityscreening AT bouzamarcos laboratoryevaluationoftwelveportabledevicesformedicinequalityscreening AT donndelingerdavidv laboratoryevaluationoftwelveportabledevicesformedicinequalityscreening AT gebenlaurac laboratoryevaluationoftwelveportabledevicesformedicinequalityscreening AT berniermatthewc laboratoryevaluationoftwelveportabledevicesformedicinequalityscreening AT newtonpauln laboratoryevaluationoftwelveportabledevicesformedicinequalityscreening AT fernandezfacundom laboratoryevaluationoftwelveportabledevicesformedicinequalityscreening |